Mimi Lee | Cheif of Precision Medicine
GeneDx

Dr. Mimi Lee serves as Chief Precision Medicine Officer at GeneDx, where she leads the company’s efforts to make precision medicine the standard of care. A physician–scientist and healthcare innovator, Dr. Lee is driving GeneDx’s vision to harness the power of genomics to predict, prevent, and optimize health outcomes throughout every stage of life.  At GeneDx, Dr. Lee is focused on translating genomic insights into real-world clinical and regulatory impact. helping ensure that every therapy is developed with purpose, precision, and patient benefit. She works across the healthcare ecosystem – partnering with policymakers, health systems, biopharmaceutical companies, payers, and advocacy groups – to accelerate the adoption of precision medicine and strengthen GeneDx’s global network of collaborators. Her leadership is central to advancing the company’s mission to move from today’s reactive model of diagnosing rare diseases after symptoms arise to a future where genomes are sequenced at birth, empowering healthier lives from the very start.  Before joining GeneDx, Dr. Lee served at the Advanced Research Projects Agency for Health (ARPA-H), where she designed and directed high-impact public–private programs to advance individualized genetic medicines, including the landmark THRIVE initiative (Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines). She brings more than two decades of experience spanning academia, biotechnology, and global industry, with previous leadership roles at Samsung Bioepis, Novartis Institutes for Biomedical Research, and BioMarin.  Dr. Lee earned her MD–PhD in Neuroscience from the Albert Einstein College of Medicine as part of the NIH Medical Scientist Training Program. She holds an AB in Chemistry and East Asian Languages and Civilizations from Harvard University, completed her residency training at Washington University School of Medicine in St. Louis and the University of California, San Francisco, and holds additional certifications in Bioethics from Columbia University and Psychedelic-Assisted Therapy from the California Institute of Integral Studies.